COMPOSITION:

Each capsule contains delayed release pellets of esomeprazole magnesium tri hydrate equivalent to Esomeprazole…. 20 mg

INDICATIONS:

Treatment of Gastroesophageal Reflux Disease (GERD)

Healing of Erosive Esophagitis

ESSO (ESOMEPRAZOLE) is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4-8 weeks of treatment, an additional 4-8-week course of ESSO (ESOMEPRAZOLE) may be considered.

Maintenance of Healing of Erosive Esophagitis

ESSO (ESOMEPRAZOLE) is indicated to maintain symptomatic resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months.

Symptomatic Gastroesophageal Reflux Disease

ESSO (ESOMEPRAZOLE) is indicated for treatment of heartburn and other symptoms associated with GERD.

H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence

ESSO (ESOMEPRAZOLE) in combination with amoxicillin and clarithromycin is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.

PRESENTATION:

Available in Alu-Alu blister pack of 1×14 capsules